bi logo
Market Research Panel
Sign up to the Market Research Panel Panel Members - Log In
 
Home
About Us
OUR SERVICES
OUR EXPERIENCE
COMPANY NEWS
CONTACT US
Drug Safety Institute
Online Global Recruiting
RELATED ARTICLES
 - Acomplia
 - Adderall XR
 - Advair
 - Advair Diskus
 - Advate
 - Advicor
 - Agilect
 - Aldara
 - Aldurazyme
 - Allegra D
 - Aloxi
 - Alphagan
 - Altace
 - Alvesco
 - Amadeus
 - Amiodarone
 - Androderm
 - AndroGel
 - Apokyn
 - Apotex
 - Aranesp
 - Arava
 - Arimidex
 - Arixtra
 - Asmanex
 - Atacand
 - Avalide
 - Avandamet
 - Avandia
 - Avapro
 - Avastin
 - Avelox
 - Avinza
 - Benicar
 - Bextra
 - Bexxar
 - Biaxin
 - Bidil
 - Boniva
 - Casodex
 - Celebrex
 - Celexa
 - Certican
 - Ciprodex
 - Clarinex
 - Claritin
 - Codeprex
 - Combivir
 - Connetics
 - Coreg
 - Crestor
 - Cyclosporine
 - Cymbalta
 - Definity
 - Eligard
 - Eloxatin
 - Emend
 - Emtriva
 - Enablex
 - Entereg
 - Epivir
 - Epogen
 - Equetro
 - ERD
 - Evoclin
 - Exanta
 - Fabrazyme
 - Factive
 - Famotidine
 - Femtrace
 - Fentanyl
 - Flolan
 - Flovent Forte
 - Floxin
 - Flumist
 - Fluzone
 - Focalin
 - Fortamet
 - Galida
 - Genasense
 - Gliadel
 - Glucophage XR
 - Glucovance
 - Gonal F
 - Healthpoint
 - Hepsera
 - Infanrix
 - Inspra
 - Iressa
 - Isotretinoin
 - Ketek
 - Ketorolac
 - Kineret
 - Klor-Con M15
 - Kogenate FS
 - Lantus
 - Levitra
 - Levixa
 - Lipitor
 - Lovenox
 - Lucentis
 - Lumigan
 - Lunesta
 - Luvox
 - Menostar
 - Milrinone
 - Mobic
 - Mucinex
 - Mylotarg
 - Namenda
 - Nasacort HFA
 - Nasonex
 - Navelbine
 - Neulasta
 - Neupogen
 - Nexium
 - Opticlik
 - Orathecin
 - Ovcon
 - Oxis
 - Panretin
 - Panzem
 - Paxil CR
 - Plavix
 - Plenaxis
 - Pravachol
 - Preos
 - Prestara
 - Prevacid
 - Prevacid IV
 - Prevacid Solutab
 - Prevnar
 - Prialt
 - Propecia
 - Proquad
 - Provigil
 - Prozac Weekly
 - Pulmicort
 - Quixin
 - Ranexa
 - Rapamune
 - Raptiva
 - Redux
 - Relafen
 - Relenza
 - Remicade
 - Remune
 - Requip
 - Restasis
 - Rhinocort
 - Ritalin LA
 - Sanctura
 - Sculptra
 - Sensipar
 - Seretide
 - Seroquel
 - Servier
 - Sicor
 - Strattera
 - Sustiva
 - Symbicort
 - Tarceva
 - Targetin
 - Taxotere
 - Temodar
 - Terazol
 - Topiglan
 - Trizivir
 - Truvada
 - Tysabri
 - Uroxatral
 - US Oncology
 - Valproate
 - Ventavis
 - Vesicare
 - Vidaza
 - Viracept
 - Viread
 - Welchol
 - Xalatan
 - Xeloda
 - Xenical
 - Xopenex
 - Zegerid
 - Zelnorm
 - Zemaira
 - Zerit XR
 - Zetia
 - Ziagen
 - Zimycan
 - Zoladex
 - Zometa
 - Zomig Nasal Spray
 - Zyban
 
 
   
 

Tuesday, November 30, 2004

UNITEDHEALTH ACQUIRES DEFINITY FOR APPROXIMATELY $300 MILLION

UnitedHealth Group will acquire privately held Definity Health Corp., a provider of health benefits to employers using self-funded benefit plans, for approximately $300 million in cash. The move is designed to increase UnitedHealth's presence in the "fast-growing high-deductible benefits business," according to the Wall Street Journal.

A health care brand, Definity Health will operate within the Uniprise business segment of UnitedHealth.

Following the merger, Definity Health customers will have access to UnitedHealth's network of 460,000 physicians and other care providers, as well as 4,000 hospitals, according to a press release.

Subject to government approval, the transaction is expected to be completed before the end of the year. Upon completion of the acquisition, UnitedHealth expects it will serve approximately 2.5 million people.

United Health said the acquisition will be slightly accretive to UnitedHealth Group's earnings per share.

 
 
AUSTIN 512-369-9100
Contact Location - Chicago
Contact Location - Los Angeles
Contact Location - Miami
Contact Location - New York
Contact Location - Raleigh
Contact Location - Raleigh
Contact Location - San Francisco
Contact Location - Ottawa, Canada
Contact Location - Switzerland
     

Copyright © 2006 Brand Institute, Inc.   |  home  |  about us  |  our services  |  our experience  |  company news  |  contact us  |  site map